Clinical trials: Depression Severe
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder
The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT02902601
- Testing
- JNJ-54175446, 600 mg, JNJ-54175446, 150 mg
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 70 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
- Trial name
- NCT05109195
- Testing
- Standard of Care (SOC)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study of Intermittent Doses of CERC-301 in MDD
There is a significant unmet medical need for rapidly acting treatment of subjects with severe major depressive disorder (MDD) who have not adequately responded to antidepressant therapy.
- Trial name
- NCT02459236
- Testing
- CERC-301
- Where
- 13 sites in United States
- Volunteers
- 115 people
- Sponsor
- Avalo Therapeutics, Inc.
Major Depressive Disorder
Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder
To evaluate the long-term safety of desvenlafaxine sustained release (DVS-233SR) during open-label treatment of outpatients with major depressive disorder (MDD).
- Trial name
- NCT00452595
- Testing
- DVS-233 SR (desvenlafaxine sustained release )
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Depression
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression.
- Conditions
- Major Depressive Disorder, Depression, Healthy
- Trial name
- NCT06570369
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to study a closed-loop transcranial alternating current stimulation (tACS) device to evaluate feasibility of the product in a clinical trial and collect preliminary data on potential effects…
- Trial name
- CL-tACS RCT (NCT06874374)
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pulvinar Neuro, LLC
Depression, Bipolar
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or…
- Trial name
- APOLLO (NCT03423680)
- Testing
- Abilify 2, 5, 10, 15mg (Tablet)
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
- Trial name
- MADDRE (NCT01397903)
- Where
- 27 sites in Greece
- Volunteers
- 545 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.
- Trial name
- NCT00766870
- Testing
- Lu AA34893, Venlafaxine extended release
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in…
- Trial name
- CES-MDD (NCT05384041)
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Fisher Wallace Laboratories
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Depressive Disorder, Major
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive…
- Trial name
- Moonlight-1 (NCT06785012)
- Testing
- JNJ-89495120
- Where
- 44 sites in United States
- Volunteers
- 105 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets
The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total scores from baseline to…
- Trial name
- NCT03739632
- Testing
- Hypidone Hydrochloride tablets
- Where
- 19 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Disorder
ALTO-300 in Depression (ALTO-300-004)
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05157945
- Testing
- ALTO-300 PO Tablet
- Where
- 4 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder.
- Trial name
- NCT03487198
- Testing
- Brexpiprazole
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Otsuka Beijing Research Institute
Major Depressive Disorder
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation…
- Trial name
- NCT00063206
- Testing
- DVS-233 SR
- Volunteers
- 247 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
This study will investigate the tolerability and pharmacokinetics of Hypidone Hydrochloride by multiple doses in 36 healthy male and female subjects who are of 18 to 55 years old.
- Trial name
- NCT04598607
- Testing
- Hypidone Hydrochloride tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.